| Schedule of financial information by reportable segments |
Financial information by reportable segment is as follows: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, 2026 | | (in thousands) | | Generics and Other | | Rare Disease and Brands | | Corporate and Unallocated | | Total | | Net Revenues | | $ | 109,220 | | $ | 128,242 | | $ | — | | | $ | 237,462 | | | Cost of sales (excluding depreciation and amortization) | | 59,592 | | | 33,990 | | | — | | | 93,582 | | | Research and Development expense | | 7,789 | | | 2,811 | | | — | | | 10,600 | | | Selling, general, and administrative expense | | 1,522 | | | 55,188 | | | 16,945 | | | 73,655 | | | Depreciation and amortization | | — | | | — | | | 20,919 | | | 20,919 | | | Contingent consideration fair value adjustment | | — | | | — | | | (182) | | | (182) | | | Operating Income (Loss) | | $ | 40,317 | | | $ | 36,253 | | | $ | (37,682) | | | $ | 38,888 | | | | | | | | | | | | Unrealized gain on investment in equity securities | | $ | — | | | $ | — | | | $ | 5,753 | | | $ | 5,753 | | | Interest expense, net | | — | | | — | | | (3,769) | | | (3,769) | | | Other expense, net | | — | | | — | | | (651) | | | (651) | | | Income (Loss) Before Income Tax Expense | | $ | 40,317 | | | $ | 36,253 | | | $ | (36,349) | | | $ | 40,221 | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended March 31, 2025 | | (in thousands) | | Generics and Other | | Rare Disease and Brands | | Corporate and Unallocated | | Total | | Net Revenues | | $ | 103,040 | | $ | 94,082 | | $ | — | | | $ | 197,122 | | | Cost of sales (excluding depreciation and amortization) | | 46,501 | | | 26,536 | | | — | | | 73,037 | | | Research and Development expense | | 6,588 | | | 3,976 | | | — | | | 10,564 | | | Selling, general, and administrative expense | | 1,408 | | | 42,436 | | | 32,684 | | | 76,528 | | | Depreciation and amortization | | — | | | — | | | 22,891 | | | 22,891 | | | Contingent consideration fair value adjustment | | — | | | — | | | (12,092) | | | (12,092) | | | Operating (Loss) Income | | $ | 48,543 | | $ | 21,134 | | $ | (43,483) | | $ | 26,194 | | | | | | | | | | | Unrealized loss on investment in equity securities | | $ | — | | | $ | — | | | $ | (921) | | | $ | (921) | | | Interest expense, net | | — | | | — | | | (5,484) | | | (5,484) | | | Other income, net | | — | | | — | | | 198 | | | 198 | | | Income (Loss) Before Income Tax Expense | | $ | 48,543 | | $ | 21,134 | | $ | (49,690) | | | $ | 19,987 | |
|